

Form to Document Refusal of Treatment for Latent Tuberculosis Infection

Patient Name: _____ Date of Birth: _____

rou have a lifetime risk of developing TB disease. Your physician has preatment with Isoniazid, Rifapentine, Rifabutin or Rifampin. Treatme prevent the disease in most individuals who complete the recommen medication and the appropriate medical supervision will be provided	nt with any of these drugs will ded course of treatment. The	
In the United States, unless treated, approximately 5% of persons whom. <i>tuberculosis</i> will develop TB disease in the first one to two years affevelop disease sometime later in life. In all, approximately 10% of persons who are infected with <i>M. tuberculosis</i> , TB disease will develop impaired immune systems who are infected with <i>M.tuberculosis</i> have disease.	fter infection and another 5% will ersons with normal immune p at some point. <mark>Persons with</mark>	
have read the information on this form about preventative TB therapy. I believe I inderstand the benefits and risks of taking preventative therapy. I have had an opportunity o ask questions which were answered to my satisfaction.		
supervision in order to decrease my risk for developing TB dise	benefits and risks of taking preventative therapy. I have had an opportunity	
ntention to take the medication, I understand that the Health o advise me on this matter.	-	
ntention to take the medication, I understand that the Health	-	
ntention to take the medication, I understand that the Health	-	
ntention to take the medication, I understand that the Health to advise me on this matter.	Department will be available	
ntention to take the medication, I understand that the Health o advise me on this matter. Signature of person refusing treatment (or parent or guardian)	Department will be available Date	
ntention to take the medication, I understand that the Health to advise me on this matter. Signature of person refusing treatment (or parent or guardian) Printed Name	Department will be available Date Relationship to patient	

TB-102 November 2024